Precision Management of Advanced Non-Small Cell Lung Cancer
Journal
Annual Review of Medicine
Journal Volume
71
Pages
117-136
Date Issued
2020
Author(s)
Abstract
The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non-small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non-small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future. ? 2020 by Annual Reviews. All rights reserved.
SDGs
Other Subjects
anaplastic lymphoma kinase; antineoplastic agent; B Raf kinase; epidermal growth factor receptor; immune checkpoint inhibitor; immunological antineoplastic agent; unclassified drug; anaplastic lymphoma kinase; angiogenesis inhibitor; B Raf kinase; epidermal growth factor receptor; programmed death 1 ligand 1; programmed death 1 receptor; protein kinase inhibitor; advanced cancer; c ros1 oncogene; cancer immunotherapy; cancer prognosis; cancer survival; gene mutation; human; lung adenocarcinoma; molecularly targeted therapy; non small cell lung cancer; oncogene; personalized medicine; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; randomized controlled trial (topic); Review; genetics; lung adenocarcinoma; lung tumor; non small cell lung cancer; personalized medicine; squamous cell carcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf
Publisher
Annual Reviews Inc.
Type
review